β-Carotene inhibits neuroblastoma cell invasion and metastasis in vitro and in vivo by decreasing level of hypoxia-inducible factor-1α

Journal of Nutritional Biochemistry

Volumn 25, Issue 6, 2014, Pages 655-664

  Kim, Yoo Sun ^a   Lee, Hyun Ah ^a   Lim, Ji Ye ^a   Kim, Yang ^b   Jung, Chang Hwan ^b   Yoo, Sang Ho ^b   Kim, Yuri ^a  

^a Ewha Womans University   (South Korea)

^b Sejong University   (South Korea)

Author keywords

Hypoxia inducible factor 1 ; Metastasis; Neuroblastoma; Carotene

Indexed keywords

BETA CAROTENE; GELATINASE A; GELATINASE B; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MATRIX METALLOPROTEINASE 15; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN; ANTINEOPLASTIC AGENT; HIF1A PROTEIN, HUMAN; MMP2 PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; METASTASIS; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PROTEIN EXPRESSION; TUMOR INVASION; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL HYPOXIA; CELL MOTION; CHEMISTRY; DIET SUPPLEMENTATION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; GERMFREE ANIMAL; LIVER NEOPLASMS; MALE; METABOLISM; NEUROBLASTOMA; NUDE MOUSE; PATHOLOGY; RANDOMIZATION; SECONDARY; TUMOR CELL LINE;

MUS; MUS MUSCULUS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BETA CAROTENE; CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; DIETARY SUPPLEMENTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEUROBLASTOMA; RANDOM ALLOCATION; SPECIFIC PATHOGEN-FREE ORGANISMS; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899929201     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2014.02.006     Document Type: Article

References (72)

1. Grovas A., Fremgen A., Rauck A., Ruymann F.B., Hutchinson C.L., Winchester D.P., et al. The National Cancer Data Base report on patterns of childhood cancers in the United States. Cancer 1997, 80:2321-2332.
2. Asgharzadeh S., Salo J.A., Ji L., Oberthuer A., Fischer M., Berthold F., et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol 2012, 30:3525-3532.
3. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003, 3:203-216.
4. Naranjo A., Parisi M.T., Shulkin B.L., London W.B., Matthay K.K., Kreissman S.G., et al. Comparison of (1)(2)(3)I-metaiodobenzylguanidine (MIBG) and (1)(3)(1)I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2011, 56:1041-1045.
5. Sugiura Y., Shimada H., Seeger R.C., Laug W.E., DeClerck Y.A. Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res 1998, 58:2209-2216.
6. Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999, 341:1165-1173.
7. Seeger R.C., Brodeur G.M., Sather H., Dalton A., Siegel S.E., Wong K.Y., et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985, 313:1111-1116.
8. Guo J., Dong Q., Fang Z., Chen X., Lu H., Wang K., et al. Identification of miRNAs that are associated with tumor metastasis in neuroblastoma. Cancer Biol Ther 2010, 9:446-452.
9. Tse J.C., Kalluri R. Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 2007, 101:816-829.
10. Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R.A., Come C., et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939.
11. Fingleton B. Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci 2006, 11:479-491.
12. Fillmore H.L., VanMeter T.E., Broaddus W.C. Membrane-type matrix metalloproteinases (MT-MMPs): expression and function during glioma invasion. J Neuro-Oncol 2001, 53:187-202.
13. Brew K., Dinakarpandian D., Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000, 1477:267-283.
14. Erler J.T., Bennewith K.L., Nicolau M., Dornhofer N., Kong C., Le Q.T., et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006, 440:1222-1226.
15. Finger E.C., Giaccia A.J. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev 2010, 29:285-293.
16. Harris A.L. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47.
17. Lee J.H., Kim E.J., Kim D.K., Lee J.M., Park S.B., Lee I.K., et al. Hypoxia induces PDK4 gene expression through induction of the orphan nuclear receptor ERRgamma. PloS One 2012, 7:e46324.
18. Wang G.L., Semenza G.L. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem 1993, 268:21513-21518.
19. Safran M., Kaelin W.G. HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 2003, 111:779-783.
20. Lunt S.J., Chaudary N., Hill R.P. The tumor microenvironment and metastatic disease. Clin Experimental Metastasis 2009, 26:19-34.
21. Subarsky P., Hill R.P. The hypoxic tumour microenvironment and metastatic progression. Clin Experimental Metastasis 2003, 20:237-250.
22. Lin J., Cook N.R., Albert C., Zaharris E., Gaziano J.M., Van Denburgh M., et al. Vitamins C and E and beta carotene supplementation and cancer risk: a randomized controlled trial. J Natl Cancer Inst 2009, 101:14-23.
23. Pastorino U., Pisani P., Berrino F., Andreoli C., Barbieri A., Costa A., et al. Vitamin A and female lung cancer: a case-control study on plasma and diet. Nutr Cancer 1987, 10:171-179.
24. van Poppel G., Goldbohm R.A. Epidemiologic evidence for beta-carotene and cancer prevention. Am J Clin Nutr 1995, 62:1393S-1402S.
25. Ziegler R.G. A review of epidemiologic evidence that carotenoids reduce the risk of cancer. J Nutr 1989, 119:116-122.
26. Bogenmann E. A metastatic neuroblastoma model in SCID mice. Int J Cancer 1996, 67:379-385.
27. Hazuka M.B., Edwards-Prasad J., Newman F., Kinzie J.J., Prasad K.N. Beta-carotene induces morphological differentiation and decreases adenylate cyclase activity in melanoma cells in culture. J Am Coll Nutr 1990, 9:143-149.
28. Palozza P., Serini S., Maggiano N., Angelini M., Boninsegna A., Di Nicuolo F., et al. Induction of cell cycle arrest and apoptosis in human colon adenocarcinoma cell lines by beta-carotene through down-regulation of cyclin A and Bcl-2 family proteins. Carcinogenesis 2002, 23:11-18.
29. Palozza P., Serini S., Torsello A., Di Nicuolo F., Piccioni E., Ubaldi V., et al. Beta-carotene regulates NF-kappaB DNA-binding activity by a redox mechanism in human leukemia and colon adenocarcinoma cells. J Nutr 2003, 133:381-388.
30. Pradeep C.R., Kuttan G. Effect of beta-carotene on the inhibition of lung metastasis in mice. Phytomedicine 2003, 10:159-164.
31. Liu L., Li F., Cardelli J.A., Martin K.A., Blenis J., Huang S. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene 2006, 25:7029-7040.
32. Neto-Neves E.M., Dias-Junior C.A., Rizzi E., Castro M.M., Sonego F., Gerlach R.F., et al. Metalloproteinase inhibition protects against cardiomyocyte injury during experimental acute pulmonary thromboembolism. Crit Care Med 2011, 39:349-356.
33. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
34. Zonta F., Stancher B., Marletta G.P. Simultaneous high-performance liquid chromatographic analysis of free carotenoids and carotenoid esters. J Chromatogr 1987, 403:207-215.
35. Ji F., Wang Y., Qiu L., Li S., Zhu J., Liang Z., et al. Hypoxia inducible factor 1alpha-mediated LOX expression correlates with migration and invasion in epithelial ovarian cancer. Int J Oncol 2013, 42:1578-1588.
36. Xiang Z.L., Zeng Z.C., Fan J., Tang Z.Y., Zeng H.Y., Gao D.M. Gene expression profiling of fixed tissues identified hypoxia-inducible factor-1alpha, VEGF, and matrix metalloproteinase-2 as biomarkers of lymph node metastasis in hepatocellular carcinoma. Clin Cancer Res 2011, 17:5463-5472.
37. Tsai Y.P., Wu K.J. Hypoxia-regulated target genes implicated in tumor metastasis. J Biomed Sci 2012, 19:102.
38. Maris J.M. Recent advances in neuroblastoma. N Engl J Med 2010, 362:2202-2211.
39. Maris J.M., Hogarty M.D., Bagatell R., Cohn S.L. Neuroblastoma. Lancet 2007, 369:2106-2120.
40. Corvi R., Savelyeva L., Schwab M. Patterns of oncogene activation in human neuroblastoma cells. J Neuro-Oncol 1997, 31:25-31.
41. Ziegler R.G. Vegetables, fruits, and carotenoids and the risk of cancer. Am J Clin Nutr 1991, 53:251S-259S.
42. van Poppel G. Epidemiological evidence for beta-carotene in prevention of cancer and cardiovascular disease. Eur J Clin Nutr 1996, 50(Suppl 3):S57-S61.
43. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group. Ann Epidemiol 1994, 4:1-10.
44. Omenn G.S., Goodman G.E., Thornquist M.D., Balmes J., Cullen M.R., Glass A., et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996, 334:1150-1155.
45. Pham D.N., Leclerc D., Levesque N., Deng L., Rozen R. beta,beta-Carotene 15,15'-monooxygenase and its substrate beta-carotene modulate migration and invasion in colorectal carcinoma cells. The American journal of clinical nutrition 2013, 98:413-422.
46. Guruvayoorappan C., Kuttan G. Beta-carotene inhibits tumor-specific angiogenesis by altering the cytokine profile and inhibits the nuclear translocation of transcription factors in B16F-10 melanoma cells. Integ Cancer Ther 2007, 6:258-270.
47. Park S., Kim Y.S., Lee H.A., Lim Y., Kim Y. Mulberry leaf extract inhibits invasive potential and downregulates hypoxia-inducible factor-1alpha (HIF-1alpha) in SK-N-BE2C neuroblastoma cells. Biosci Biotechnol Biochem 2013, 77:722-728.
48. Ridgway P.F., Ziprin P., Alkhamesi N., Paraskeva P.A., Peck D.H., Darzi A.W. Hypoxia augments gelatinase activity in a variety of adenocarcinomas in vitro. J Surg Res 2005, 124:180-186.
49. Goh Y.I., Bollano E., Einarson T.R., Koren G. Prenatal multivitamin supplementation and rates of pediatric cancers: a meta-analysis. Clin Pharmacol Ther 2007, 81:685-691.
50. Olshan A.F., Smith J.C., Bondy M.L., Neglia J.P., Pollock B.H. Maternal vitamin use and reduced risk of neuroblastoma. Epidemiology 2002, 13:575-580.
51. Klymenko T., Brandenburg M., Morrow C., Dive C., Makin G. The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells. Mol Cancer Ther 2011, 10:2373-2383.
52. Salnikov A.V., Liu L., Platen M., Gladkich J., Salnikova O., Ryschich E., et al. Hypoxia induces EMT in low and highly aggressive pancreatic tumor cells but only cells with cancer stem cell characteristics acquire pronounced migratory potential. PloS one 2012, 7:e46391.
53. Salceda S., Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997, 272:22642-22647.
54. Kim Y. The effects of nutrient depleted microenvironments and delta-like 1 homologue (DLK1) on apoptosis in neuroblastoma. Nutr Res Pract 2010, 4:455-461.
55. Lu X., Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 2010, 16:5928-5935.
56. Liao D., Corle C., Seagroves T.N., Johnson R.S. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 2007, 67:563-572.
57. Fardin P., Barla A., Mosci S., Rosasco L., Verri A., Versteeg R., et al. A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients. Molec Cancer 2010, 9:185.
58. Semenza G.L. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Molec Biol 2000, 35:71-103.
59. Plate K.H., Breier G., Weich H.A., Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992, 359:845-848.
60. Liu Y., Li Y.M., Tian R.F., Liu W.P., Fei Z., Long Q.F., et al. The expression and significance of HIF-1alpha and GLUT-3 in glioma. Brain Res 2009, 1304:149-154.
61. Burger J.A., Kipps T.J. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006, 107:1761-1767.
62. Yang M.H., Wu K.J. TWIST activation by hypoxia inducible factor-1 (HIF-1): implications in metastasis and development. Cell Cycle 2008, 7:2090-2096.
63. Levy J., Bosin E., Feldman B., Giat Y., Miinster A., Danilenko M., et al. Lycopene is a more potent inhibitor of human cancer cell proliferation than either alpha-carotene or beta-carotene. Nutr Cancer 1995, 24:257-266.
64. Palozza P., Calviello G., Serini S., Maggiano N., Lanza P., Ranelletti F.O., et al. beta-Carotene at high concentrations induces apoptosis by enhancing oxy-radical production in human adenocarcinoma cells. Free Radic Biol Med 2001, 30:1000-1007.
65. Palozza P., Serini S., Torsello A., Di Nicuolo F., Maggiano N., Ranelletti F.O., et al. Mechanism of activation of caspase cascade during beta-carotene-induced apoptosis in human tumor cells. Nutr Cancer 2003, 47:76-87.
66. Lee H.A., Park S., Kim Y. Effect of beta-carotene on cancer cell stemness and differentiation in SK-N-BE(2)C neuroblastoma cells. Oncol Rep 2013, 30:1869-1877.
67. Yang C.M., Yen Y.T., Huang C.S., Hu M.L. Growth inhibitory efficacy of lycopene and beta-carotene against androgen-independent prostate tumor cells xenografted in nude mice. Molec Nutr Food Res 2011, 55:606-612.
68. Salgado Oloris S.C., Dagli M.L., Guerra J.L. Effect of beta-carotene on the development of the solid Ehrlich tumor in mice. Life Sci 2002, 71:717-724.
69. Liu C., Wang X.D., Bronson R.T., Smith D.E., Krinsky N.I., Russell R.M. Effects of physiological versus pharmacological beta-carotene supplementation on cell proliferation and histopathological changes in the lungs of cigarette smoke-exposed ferrets. Carcinogenesis 2000, 21:2245-2253.
70. Hwang E.S., Lee H.J. Inhibitory effects of lycopene on the adhesion, invasion, and migration of SK-Hep1 human hepatoma cells. Exp Biol Med 2006, 231:322-327.
71. Chow CK. The relative efficacy of lycopene and beta-carotene in inhibiting experimental metastasis of human hepatoma SK-Hep-1 cells in athymic nude mice. The Journal of nutrition. 2008;138:2289; [author reply 90].
72. Kozuki Y., Miura Y., Yagasaki K. Inhibitory effects of carotenoids on the invasion of rat ascites hepatoma cells in culture. Cancer Lett 2000, 151:111-115.